Norges billigste bøker

Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC

Om Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival.  As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer. This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer.

Vis mer
  • Språk:
  • Engelsk
  • ISBN:
  • 9780128228333
  • Bindende:
  • Hardback
  • Sider:
  • 150
  • Utgitt:
  • 1. februar 2023
  • Dimensjoner:
  • 201x243x14 mm.
  • Vekt:
  • 474 g.
  Gratis frakt
Leveringstid: Ukjent

Beskrivelse av Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival.  As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer. This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer.

Brukervurderinger av Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC



Gjør som tusenvis av andre bokelskere

Abonner på vårt nyhetsbrev og få rabatter og inspirasjon til din neste leseopplevelse.